Background and objective Organic anion transporting polypeptide 1B1 (OATP1B1) is an uptake transporter located at the sinusoidal membrane of human hepatocytes. This study aimed to investigate the effects of genetic polymorphism in the SLCO1B1 gene encoding OATP1B1 on the pharmacokinetics of simvastatin.
Background and objective Organic anion transporting polypeptide 1B1 (OATP1B1) is an uptake transporter located at the sinusoidal membrane of human hepatocytes. This study aimed to investigate the effects of genetic polymorphism in the SLCO1B1 gene encoding OATP1B1 on the pharmacokinetics of simvastatin.
Methods Four healthy volunteers with the homozygous SLCO1B1 c.521CC genotype, 12 with the heterozygous c.521TC genotype and 16 with the homozygous c.521TT genotype (controls) were recruited. Each study participant ingested a single 40-mg dose of simvastatin. Plasma concentrations of simvastatin (inactive lactone) and its active metabolite simvastatin acid were measured for 12 h.
Results The AUC 0-N of simvastatin acid was 120 and 221% higher in participants with the SLCO1B1 c.521CC genotype than in those with the c.521TC and c.521TT (reference) genotypes, respectively (P < 0.001). The C max of simvastatin acid was 162 and 200% higher in participants with the c.521CC genotype than in those with the c.521TC and c.521TT genotypes (P < 0.001). The C max of simvastatin acid occurred earlier in participants with the c.521CC and c.521TC genotypes than in those with the c.521TT genotype (P < 0.05). No association existed between the SLCO1B1 genotype and the elimination half-life of simvastatin acid. Moreover, no statistically significant association was seen between the SLCO1B1 genotype and the pharmacokinetics of simvastatin lactone.
Conclusions SLCO1B1 polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Raised plasma concentrations of simvastatin acid in patients carrying the SLCO1B1 c.521C variant allele may enhance the risk of systemic adverse effects during simvastatin treatment. In addition, reduced uptake of simvastatin acid by OATP1B1 into the liver in patients with the c.521C allele could reduce its cholesterol-lowering efficacy. 
Introduction
Simvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used in the treatment of hypercholesterolemia [1] . It reduces cardiovascular morbidity and mortality in high-risk patients [2] . Simvastatin is administered as an inactive lactone prodrug, which undergoes reversible non-enzymatic and carboxylesterase-mediated conversion in plasma, liver and intestinal mucosa to simvastatin acid, the active metabolite of simvastatin [1, 3] . Simvastatin acid and other simvastatin-derived active metabolites inhibit the conversion of HMG-CoA to mevalonate, which is the rate limiting step in cholesterol biosynthesis [4] . Inhibition of the HMG-CoA reductase in the liver increases the expression of low-density lipoprotein (LDL) receptors in the hepatocyte plasma membrane, enhancing the removal of LDL particles from blood and reducing plasma total and LDL cholesterol concentrations.
Large interindividual variability exists in the plasma concentrations of simvastatin and in its efficacy and risk of adverse effects. Myopathy is a relatively common adverse effect of statins, whereas the serious rhabdomyolysis is rare [5, 6] . The incidence of myopathy and rhabdomyolysis increases along with increased plasma concentrations of statins, and particularly when statins are used concomitantly with compounds that inhibit their metabolism or plasma membrane transport [7, 8] . [10, 11] . CYP3A4 inhibitors, such as itraconazole, verapamil, erythromycin and grapefruit juice, markedly elevate the plasma concentrations of both simvastatin and simvastatin acid [12] [13] [14] . In addition, genetic polymorphism in CYP3A5 was associated with simvastatin efficacy in one study [15] .
Organic anion transporting polypeptide 1B1 (OATP1B1) is a solute carrier expressed on the sinusoidal membrane of human hepatocytes [16] [17] [18] . It facilitates the hepatic uptake of many endogenous and foreign compounds, such as estrogen conjugates, bile acids and statins [16] [17] [18] [19] [20] [21] [22] [23] [24] . A common single nucleotide polymorphism (SNP) in SLCO1B1, c.521T > C (p.Val 174 Ala), has been associated with reduced activity of OATP1B1 in vitro [23, 25] and markedly increased plasma concentrations of pravastatin, rosuvastatin and pitavastatin in vivo in humans [26] [27] [28] [29] [30] . In one study performed in vitro, simvastatin lactone was not transported by OATP1B1 [23] , but there seem to be no studies directly investigating whether simvastatin acid is a substrate of OATP1B1. Simvastatin acid, however, strongly inhibits OATP1B1-mediated uptake of pravastatin in vitro, suggesting that it may also be a substrate for OATP1B1 [17, 31] . As SLCO1B1 polymorphism markedly affects the pharmacokinetics of several statins, we wanted to investigate the effects of variant SLCO1B1 genotypes on the pharmacokinetics of simvastatin and simvastatin acid in a prospective genotype panel study controlling for CYP3A5 polymorphism.
Methods

Study participants
A total of 32 young healthy Caucasian volunteers participated in the study after giving written informed consent. The study participants had been genotyped for SLCO1B1 SNPs by TaqMan allelic discrimination with an Applied Biosystems 7300 Real-Time PCR system (Applied Biosystems, Foster City, California, USA) as described previously [32] . In addition, they were genotyped for the CYP3A5*3 (g.6986A > G) allele as described previously [15] . As the CYP3A5 genotype has been associated with the efficacy of simvastatin [15] , only participants with the CYP3A5 non-expressor genotype (CYP3A5*3/*3) were recruited. The participants were selected on the basis of the SLCO1B1 c.521T > C SNP as well as the g. -11187G > A, g. -10499A > C and c.388A > G SNPs, by which the four major Caucasian haplotypes containing the c.521C allele (*5, *15, *16 and *17) can be distinguished [28, 32] . The participants were allocated into one of three groups according to the genotype. Haplotypes were assigned as described previously (Table 1 ) [32] . The control group included Table 1 Genetic background of the study participants 16 participants (eight women, eight men) with the homozygous reference genotype at each position (c.521TT group). Their mean ± SD age was 23 ± 2 years, height 174 ± 9 cm and weight 68 ± 10 kg. The second group consisted of 12 participants (five women, seven men) heterozygous for the c.521T > C SNP (c.521TC group). Their mean ± SD age was 24 ± 4 years, height 174 ± 9 cm and weight 69 ± 8 kg. The third group comprised four participants (one woman, three men) with the homozygous c.521CC genotype (c.521CC group). Their mean ± SD age was 23 ± 2 years, height 180 ± 8 cm and weight 84 ± 8 kg. The participants were ascertained to be healthy by medical history, physical examination and routine laboratory tests before they were entered in the study. One participant with the c.521TT genotype was a tobacco smoker and none used any continuous medication.
Study design
The study protocol was approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District and by the National Agency for Medicines.
Following an overnight fast, the participants ingested a single 40-mg dose of simvastatin (Zocor, Merck Sharp & Dohme, Haarlem, The Netherlands) with 150 ml water at 08:00 h. A standard warm meal was served 4 h after simvastatin ingestion and a standard light meal after 7 and 10 h. Timed blood samples (5-10 ml each) were drawn before and 0.5, 1, 1.5, 2, 3, 4, 5, 7, 9 and 12 h after simvastatin ingestion into tubes that contained ethylenediaminetetraacetic acid and were placed on ice immediately after sampling. Plasma was separated within 30 min after blood sampling and stored at -701C until analysis. Use of other drugs was prohibited for 1 week and use of grapefruit products was prohibited for 3 days before simvastatin administration.
Determination of plasma simvastatin and simvastatin acid concentrations
Plasma simvastatin and simvastatin acid concentrations were quantified by liquid chromatography-ion spray tandem mass spectrometry using the PE Sciex API 3000 LC/MS/MS system (Sciex Division of MDS Inc., Toronto, Ontario, Canada) as described previously [33, 34] . The limit of quantification was 0.05 ng/ml for simvastatin and 0.1 ng/ml for simvastatin acid. The between-day coefficients of variation were 4.1% at 0.1 ng/ml, 5.2% at 1.0 ng/ml and 3.2% at 50 ng/ml of simvastatin (n = 4), and 9.9% at 0.1 ng/ml, 7.3% at 1.0 ng/ ml and 7.0% at 50 ng/ml of simvastatin acid (n = 4).
Pharmacokinetics
The pharmacokinetics of simvastatin and simvastatin acid were characterized by the peak concentration in plasma (C max ), time to C max (t max ), elimination half-life (t 1/2 ) and area under the plasma concentration-time curve from 0 to 12 h (AUC 0-12 ) and from 0 h to infinity (AUC 0-N ).
The terminal log-linear part of each concentration-time curve was identified visually, and the elimination rate constant (k e ) was determined from log-transformed data with linear regression analysis. The t 1/2 was calculated by the equation t 1/2 = ln 2/k e . AUC was calculated by a combination of the linear and log-linear trapezoidal rules, with extrapolation to infinity, when appropriate, by division of the last measured concentration by k e .
Statistical analysis
Results are expressed as mean ± SD in the text and tables and, for clarity, as mean ± SEM in Fig. 1 . The pharmacokinetic variables of simvastatin and simvastatin acid between the SLCO1B1 c.521TT, c.521TC and c.521CC genotype groups were compared using analysis of variance and pairwise testing with the Tukey test. The t max data were analyzed by the Kruskal-Wallis test and pairwise testing with the Mann-Whitney U-test using the Bonferroni correction. The data were analyzed with the statistical program SPSS 11.0 for Windows (SPSS Inc., Chicago, Illinois, USA). On the basis of previous data on the pharmacokinetics of simvastatin [12] , the number of participants in each genotype group was estimated to be sufficient to detect a 50% larger AUC 0-N of simvastatin or simvastatin acid in participants with the c.521TC genotype than in those with the c.521TT genotype, and a 100% larger AUC 0-N in participants with the c.521CC genotype than in those with the c.521TT genotype with a power of at least 80% (a-level 5%). Differences were considered statistically significant at a P value less than 0.05.
Results
The SLCO1B1 genotype was significantly associated with the pharmacokinetics of simvastatin acid, but not with those of the parent simvastatin lactone (Fig. 1a-c , Table  2 ). The simvastatin acid C max and AUC 0-N values of one participant (no. 6) with the c.521TC genotype were more than 3 SDs above the respective mean values (Fig. 2a and  c) , and the participant was excluded from statistical analysis as an outlier. In the participants with the SLCO1B1 c.521CC genotype, the mean AUC 0-N of simvastatin acid was 120 and 221% higher, respectively, than in the participants with the c.521TC and c.521TT (reference) genotypes (P < 0.001). The mean C max of simvastatin acid was 162 and 200% higher in the participants with the c.521CC genotype than in those with the c.521TC and c.521TT genotypes (P < 0.001). In addition, the t max of simvastatin acid was significantly shorter in the participants with the c.521TC and c.521CC genotypes than in those with the c.521TT genotype (P < 0.05). The SLCO1B1 genotype had no statistically significant effect on the elimination t 1/2 of simvastatin acid (Fig. 2b , Table 2 ).
The mean AUC 0-N ratio (simvastatin acid/simvastatin) was 1.5 ± 0.4 in the participants with the c.521CC genotype, 0.7 ± 0.4 in those with the c.521TC genotype and 0.7 ± 0.2 in those with the c.521TT genotype (c.521CC vs. c.521TC, P = 0.001; c.521CC vs. c.521TT, P < 0.001) (Fig. 1c) . A tendency towards higher C max and AUC 0-N of simvastatin lactone was observed in the participants with the homozygous c.521CC genotype than in the reference group, but the differences were not statistically significant. When the outlier participant was included in the analysis, other differences remained statistically significant except for those in the AUC 0-N ratio and the simvastatin acid C max between the c.521CC and c.521TC groups (data not shown).
No statistically significant differences were seen in the pharmacokinetic variables of simvastatin acid between c.521TC heterozygous participants with different SLCO1B1 haplotypes. The mean ± SD AUC 0-N of simvastatin acid was 25.0 ± 15.3 ng h/ml in c.521TC heterozygotes with the *15 haplotype, 19.0 ± 4.0 ng h/ml in those with the *16 haplotype and 36.5 ± 43.1 ng h/ml in those with the *17 haplotype (including the outlier) (P = 0.650).
The C max and AUC 0-N of simvastatin lactone varied eight-fold and 12-fold between individual participants and those of simvastatin acid varied 25-fold and 16-fold. The variability in the C max and AUC 0-N of simvastatin acid, however, was considerably smaller within the SLCO1B1 c.521TT (six-fold and four-fold) or c.521CC (1.5-fold and 1.7-fold) genotype groups ( Fig. 2a-c) . The variability was large within the c.521TC group (17-fold and 14-fold), but this was because the outlier participant had exceptionally high values.
Discussion
This study shows that SLCO1B1 polymorphism has a marked effect on the plasma pharmacokinetics of active simvastatin acid, but not on those of the parent simvastatin lactone. The mean AUC and C max of simvastatin acid were about three-fold in participants with the SLCO1B1 c.521CC genotype as compared with those in participants with the c.521TT reference genotype. This finding supports the idea that simvastatin acid is a substrate of OATP1B1 and that it needs active transport in order to penetrate the hepatocyte plasma membrane. In contrast, the AUC and C max of the parent simvastatin lactone were only slightly and not statistically significantly different between participants with different SLCO1B1 genotypes. This indicates that simvastatin lactone either penetrates the hepatocyte plasma membrane via passive diffusion or that an uptake transporter other than OATP1B1 mediates its hepatic uptake.
Molecular size, lipophilicity and charge are the major determinants of permeability of a lipid membrane to a drug. The molecular weight of simvastatin acid is 437 and that of simvastatin lactone is 419. Simvastatin lactone is considerably more lipophilic than simvastatin acid, with experimentally determined octanol/water partition coefficients (logD 7.0 , at pH 7.0) of 4.40 for simvastatin lactone and 1.88 for simvastatin acid [35] . The pKa (dissociation constant) of simvastatin acid is 4.31 and that of simvastatin lactone is 13.49 (values obtained from the SciFinder Database, American Chemical Society). Thus, simvastatin acid is almost completely ionized (charged) in the human plasma with a pH of about 7.4, whereas the lactone is almost completely in the un-ionized form. As simvastatin acid is ionized in the plasma and because it is only mildly lipophilic, it poorly penetrates the hepatocyte plasma membrane via passive diffusion and thus requires active hepatic uptake. On the other hand, the more lipophilic and neutral simvastatin lactone may diffuse through the plasma membrane with relative ease. Similarly to simvastatin acid, the hydrophilic OATP1B1-substrate pravastatin (logD 7.0 -0.47 [35] , pKa 4.31) is almost completely ionized at the plasma pH and the SLCO1B1 c.521C allele is associated with markedly increased plasma pravastatin concentrations [26] [27] [28] .
The highest C max and AUC of simvastatin acid were seen in one participant with the SLCO1B1 c.521TC genotype, who was clearly an outlier among the study participants (Fig. 2) . The diplotype of that participant was *1A/*17. Two other participants also had this diplotype, but they had considerably lower simvastatin acid C max and AUC values. It is likely that characteristics other than SLCO1B1 genotype (e.g. genetic variability in carboxylesterase, CYP3A4, CYP2C8 or UDP-glucuronosyltransferase) also contributed to the high C max and AUC of simvastatin acid observed in this participant, but further studies beyond the scope of this investigation are required to determine the underlying causes. As all participants in the present study were non-expressers of CYP3A5, however, its polymorphism cannot explain the finding.
The pattern of differences in the pharmacokinetics of simvastatin and simvastatin acid between participants with the c.521CC genotype and those with the c.521TT genotype is very similar to the changes observed during concomitant use of simvastatin with gemfibrozil. Gemfibrozil 1200 mg/day raised the AUC of simvastatin acid about 2.9-fold and that of simvastatin lactone about 1.4-fold [33] . Gemfibrozil does not inhibit CYP3A4 [33] , but it and its glucuronide conjugate inhibit CYP2C8 and OATP1B1 in vitro [36, 37] . Considering the similarities in the effects of gemfibrozil and SLCO1B1 polymorphism on simvastatin pharmacokinetics, it appears that inhibition of the OATP1B1-mediated hepatic uptake of simvastatin acid could be the main mechanism of the pharmacokinetic interaction between gemfibrozil and simvastatin. Cyclosporine also markedly increases the plasma concentrations of simvastatin-derived inhibitors of HMG-CoA reductase [38] . Like gemfibrozil, cyclosporine is an inhibitor of OATP1B1 [20] , but it also inhibits CYP3A4 and the P-glycoprotein efflux transporter [39, 40] . In addition, cyclosporine inhibits the OATP1B3, OATP2B1 and the sodium/taurocholate cotransporting polypeptide transporters, which mediate the uptake of rosuvastatin in vitro [41] . No published data exist on the role of these transporters in the uptake of simvastatin or simvastatin acid. Concomitant use of simvastatin with gemfibrozil, cyclosporine or a potent CYP3A4 inhibitor is associated with an increased risk of myopathy and rhabdomyolysis [5] [6] [7] [8] .
OATP1B1-mediated uptake of statins into hepatocytes can be important in terms of enhancing their therapeutic efficacy and reducing their concentrations in peripheral blood [42] . Thus, reduced hepatic uptake of the active simvastatin acid in participants carrying the SLCO1B1 c.521C variant allele may result in both a reduced cholesterol-lowering efficacy and an increased risk of systemic adverse effects. In Japanese patients using pravastatin, atorvastatin or simvastatin, the SLCO1B1 c.521TC genotype was associated with impaired cholesterol-lowering efficacy as compared with the c.521TT genotype [43] . In addition, the effect of a single 40-mg dose of pravastatin on hepatic cholesterol synthesis was reduced in Caucasian carriers of the SLCO1B1*17 Data are mean ± SD; t max data are median (range). C max , peak plasma concentration; t max , time to C max ; t 1/2 , elimination half-life; AUC 0-12 , area under the plasma concentration-time curve from 0 to 12 h; AUC 0-N , area under the plasma concentration-time curve from 0 h to infinity. a haplotype containing c.521C [44] . Moreover, the SLCO1B1*15 haplotype, also containing c.521C, has been associated with myopathy induced by pravastatin or atorvastatin in Japanese patients [45] . The SLCO1B1 c.521T > C SNP is common in Caucasian and Asian populations, with a minor allele frequency of about 15-20% in Caucasians and 10-15% in Asians [32, 46] . Therefore, SLCO1B1 polymorphism is likely to play a major role in interindividual variability in the pharmacokinetics of simvastatin, and possibly in its efficacy and toxicity, at the population level.
In conclusion, genetic polymorphism in SLCO1B1, encoding the hepatic uptake transporter OATP1B1, markedly affects the plasma concentrations of simvastatin acid, the active form of the HMG-CoA reductase inhibitor simvastatin. Genetic variability in OATP1B1 function can have clinically important consequences for the balance of risks and benefits of simvastatin treatment. 
